Eprex warning issued, but no ban

Sibbald, Barbara
March 2004
CMAJ: Canadian Medical Association Journal;3/2/2004, Vol. 170 Issue 5, p778
Academic Journal
Reports on the decision of Health Canada not to ban the subcutaneous injection of the antianemia drug Eprex from Janssen-Ortho. Reason for not banning Eprex according to Health Canada spokesperson Jirina Vik; Advice given by the Canadian Society of Nephrology on administering the epoetin alfa drug; Blood disease linked to the drug.


Related Articles

  • Bufexamac : revocation of marketing authorization.  // WHO Drug Information;2010, Vol. 24 Issue 2, p111 

    The article discusses an announcement from pharmaceutical manufacturer Janssen-Ortho Inc. in which it was indicated that the sale of the drug ceftobiprole medocaril will be discontinued as of April 16, 2010.

  • Morphine-related AEs possible in babies of nursing mothers.  // Reactions Weekly;10/18/2008, Issue 1224, p2 

    The article reports on the issuance by Janssen Ortho of a Health Canada-endorsed 'Dear Health Care Professional letter' highlighting the possibility of morphine-related adverse events (AE) in breastfed babies of nursing mothers, especially ultrarapid codeine metabolisers who receive...

  • Severe skin and hypersensitivity reactions reported with etravirine.  // Reactions Weekly;10/24/2009, Issue 1275, p3 

    The article describes the case of severe skin and hypersensitivity reactions in patients given with etravirine as part of a combination therapy for HIV infections. It references two studies both conducted by Janssen-Ortho Inc. in 2009. Reports received by Tibotec concerning the adverse effects...

  • Ceftobiprole medocaril: discontinuation of sale.  // WHO Drug Information;2010, Vol. 24 Issue 2, p111 

    The article discusses an announcement which the pharmaceutical manufacturer Janssen-Ortho Inc. made in 2010 in which it was indicated that the sale of the drug Zeftera would be discontinued.

  • Eprex prescribing information revised in Canada.  // Reactions Weekly;1/24/2004, Issue 985, p2 

    Reports on the revision of Eprex prescribing information in Canada. Formulations of the drug produced by Janssen Ortho Inc.; Importance of the drug to the treatment of patients with chronic renal failure; Association of pure red cell aplasia cases with human serum albumin-free formulation Eprex.

  • Drug safety legislation closer to passing. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;7/8/2014, Vol. 186 Issue 10, p736 

    The article reports that the bill Protecting Canadians Against Unsafe Drugs has passed second reading in the Canadian House of Commons in June 2014. The legislation amends the Food and Drugs Act to bolster regulation of prescription and over-the-counter drugs and other therapies and medical...

  • New safety information for epoetin-α, darbepoetin-α.  // Reactions Weekly;4/28/2007, Issue 1149, p1 

    The article reports that Janssen-Ortho and Amgen, in association with Health Canada, have issued a letter and a Public Communication advising of new safety information and labelling changes for epoetin-α and darbepoetin-α. The health risks posed by erythropoeisis-stimulating agents (ESA)...

  • WPI students offer local companies valuable technical consulting services. Rosa, Taina // Caribbean Business;4/19/2001, Vol. 29 Issue 16, p46 

    Reports on the offer of Worcester Polytechnic Institute students for technical consulting services to local companies in Puerto Rico. Social implications of the offer; Plan of developing forest reserves by the students and Janssen-Ortho; Proposals of the local companies and the Virtual...

  • Two-ply label expands drug label content.  // Packaging Digest;Sep2000, Vol. 37 Issue 10, p110 

    Focuses on National Label's development of unique two-ply label for use in the Canadian launch of Janssen-Ortho's Floxin antibacterial agent product. Space requirements for the label; Specifications considered during label development; Work done with FLEXcon to come up with a label structure...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics